Abstract-Myeloperoxidase (MPO) is a hemoprotein normally released from activated monocytes and neutrophils.
N ormal human pregnancy is associated with maternal systemic inflammation that is exaggerated in preeclampsia, the pregnancy disorder characterized by hypertension developing after the 20th week of gestation and proteinuria. Preeclampsia is associated with increased neutrophil counts. 1 Peripheral blood leukocytes are activated in women with normal third trimester pregnancies compared with nonpregnant patients. Leukocytes in normal pregnancy have increased markers of activation (CD11b, CD14, CD64, and intracellular reactive oxygen species), which are further increased in preeclampsia. 2, 3 Monocytes are also activated in pregnancy as evidenced by elevated surface expression of CD11b, CD14, and CD64 by the third trimester of pregnancy. 2 Monocyte activation progressively increases and peaks at 29 to 36 weeks of gestation. 4 There are several lines of evidence of neutrophil activation during preeclampsia, including the following: (1) greater basal 3 and N-formylmethionyl-phenylalanine (fMLP)-induced superoxide production 5 ; (2) increased CD11b expression basally in neutrophils from women with preeclampsia compared with normal pregnancies 3, 5 ; and (3) increased neutrophil elastase. 6 Myeloperoxidase (MPO) is a hemoprotein normally produced and released by activated monocytes and neutrophils. It is traditionally recognized as a microbicidal enzyme primarily through the action of hypochlorous acid. MPO is associated with vascular dysfunction and is mechanistically linked to the pathophysiology of numerous vascular inflammatory diseases, including arteriosclerosis and coronary artery disease. 7, 8 Elevated circulating MPO levels are a risk factor of myocardial events in patients with coronary artery disease. 9, 10 There is a strong relationship between serum MPO levels and endothelial dysfunction in humans. 11 Patient with cardiovascular disease (diagnosed as coronary artery disease, peripheral arterial disease, or cerebral vascular disease) and the highest quartile of serum MPO were Ͼ6 times as likely to have endothelial dysfunction assessed by brachial artery flow-mediated dilation than patients in the lowest quartile. 11 MPO has been shown to mediate oxidation of lipoproteins and to catalyze nitration of tyrosine residues and has been implicated in the depletion of endothelial-derived NO. [12] [13] [14] [15] [16] Once in the circulation, MPO can become sequestered in the subendothelial space through a process of heparin glycosaminoglycan-dependent binding and endothelial transcytosis, resulting in its accumulation in the endothelial cell matrix. 12 There it can be a potent source of reactive oxygen and nitrogen species and consume antioxidants. 12, 17, 18 Activated MPO also catalyzes oxidation of nitrite and NO, ultimately causing nitration of protein tyrosines. [12] [13] [14] [15] Likewise, increased nitrotyrosine in blood vessels of the placenta and peripheral circulation of the mother 19, 20 is suggestive of MPO overactivity in the vasculature during preeclampsia. There are reports of increased or unchanged MPO in the circulation of women with preeclampsia. 21 Women with a history of preeclampsia are at increased risk for poor cardiovascular health later in life. 22 These observations prompted us to examine MPO levels in the placenta and circulation of women with preeclampsia.
Methods
Preeclampsia was defined using the criteria of gestational hypertension, proteinuria and hyperuricemia, and reversal of hypertension and proteinuria after delivery. Gestational hypertension was defined as systolic blood pressure Ͼ140 mm Hg systolic or diastolic blood pressure Ͼ90 mm Hg arising after 20 weeks' gestation in a previously normotensive woman. Proteinuria was defined as Ͼ300 mg of protein in a 24-hour urine collection, Ͼ2ϩ on a voided or Ͼ1ϩ on a catheterized random urine sample, or a random urine protein:creatinine ratio of Ͼ0.3. Hyperuricemia was defined as Ͼ1 SD above normal for the given gestational age (at term: Ͼ5.5 mg/dL [3.3 mmol/L]). Control groups were composed of women with uncomplicated, normotensive pregnancies who delivered healthy, non-small-for-gestational-age babies. Patients with multiple gestations, chronic hypertension, diabetes, premature rupture of membranes, renal disease or other significant metabolic disorder, or a history of illicit drug use were excluded. The institutional review board approved the study, and written informed consent was obtained. Procedures followed were in accordance with institutional guidelines.
Placental biopsies were obtained immediately after cesarean delivery from a site between the placental rim and cord insertion. Clinical data for these patients are provided in Table 1 . The tissue was quickly washed 3 times in physiological saline, frozen in liquid nitrogen, and stored at Ϫ70°C until use. Placental extracts were prepared from Ϸ100-mg wet weight placental biopsy samples. Total proteins from placental tissues were extracted by homogenizing by sonication (Ultrasonic Processor, Tekmar, microprobe setting 70 for 30 seconds) in 4 volumes of 1ϫ Laemmli buffer (50 mmol/L of Tris HCl [pH 6.8], 2% SDS, and 10% glycerol) containing 5 mmol/L of dithiothreitol, 0.5 mmol/L of PMSF, 1 mmol/L of sodium vanadate, and 1.0 L/mL of a protease inhibitor mixture. 23 Protein was determined by the BioRad protein assay. Samples were diluted into sample diluting buffer (20 mmol/L of phosphate buffer [pH 7.4] containing 2 mg/mL of BSA, 0.1% Tween 20, and 0.2% sodium azide) for the MPO ELISA, and MPO levels were as described below.
EDTA plasma samples were obtained from normal weight preeclamptic (nϭ11; 35.5 weeks gestation) and gestationally agematched at delivery control normal pregnancies (nϭ13; 36 weeks gestation) with no sign of infection but delivering early. A second set of control subjects (nϭ17) with 2 blood samples, 1 during gestation (32.1 week) and a second near delivery (38 weeks), was used for comparison of MPO levels in the circulation during pregnancy and preeclampsia. Clinical data for these patients are provided in Table 2 . MPO concentrations were measured using ELISA. The accuracy of measuring MPO in previously frozen EDTA plasma was confirmed using MPO ELISA assays from 2 companies (Calbiochem and Assay Designs). Our preliminary experiments indicated that EDTA plasma yielded comparable results to heparized plasma or spiked plasma using fresh or 1 freeze-thaw plasma. The Calbiochem ELISA standard curve was linear from 1 to 25 ng of MPO per milliliter. The sensitivity of the assay was 1.5 ng/mL with interassay and intraassay variation of 8%. The Assay Designs (ELISA) standard curve was linear from 0.39 to 12 ng of MPO per milliliter with a sensitivity of 0.13 ng/mL with interassay variation of 7% and intra-assay variation of 5%.
Immunohistochemistry was used to determine MPO localization in the placenta from control normal pregnancies (nϭ7) and preeclamptic pregnancies (nϭ5) using previously published protocols. Patient data for these samples are provided in Table 3 with the exception of early pregnancy samples from pregnancy terminations at 7.5 and 24.0 weeks (nϭ2 at each time point). These patients had no complications, including normal blood pressures. Briefly, placental samples were fixed 3% paraformaldehyde for 30 minutes followed by 5%, 10%, and 15% sucrose PBS, then embedded in OCT. Samples were stored at Ϫ80°C until sectioned. Anti-MPO antibody (rabbit polyclonal, Calbiochem, La Jolla, CA) at a 1:200 dilution was used to localize MPO. 24 -26 The primary antibody was omitted as a negative control. Gestational increases in MPO localization in the floating villi from normal pregnancy placenta were used as a positive control. 27 Cytokeratin was stained at 1:200 antibody dilution (rat monoclonal IgG). 26 For heparin treatment of patients, 16 women (age: 25Ϯ1.4 years; 365Ϯ38 postpartum) with previous normal pregnancies at a mean of 1 yearϮ38 days and 15 women with previous preeclamptic pregnancies (age: 29Ϯ4 years; 388Ϯ30 days postpartum) with normal blood pressures and body mass index were recruited for treatment with heparin (summary patient data in Table 4 ). All of the women fasted overnight, and initial blood specimens were collected via an 18-gauge intravenous line; this is the "preheparin" sample. If hematocrit and platelets were normal (hematocrit: Ͼ35%; platelets: Ͼ100 000), women received injection of 75 IU of heparin per kilogram of body weight intravenously. After 15 minutes, 20 mL of venous blood was collected as the "postheparin" sample. Samples were stored at Ϫ70°C until use.
Statistical comparisons were by unpaired Student's t test, 1-or 2-way ANOVA, or Dunn's test as required, and meansϮSEs are reported. P values Ͻ0.05 were considered significant.
Results

MPO in Placental Extracts
Placental extracts were prepared from preeclamptic (nϭ27; 36.4 weeks gestation) and control (nϭ43; 39.1 week gestation) placentas. MPO concentrations in placental extracts from women with preeclampsia were significantly higher than in normal control subjects (546Ϯ62 versus 347Ϯ32 ng/mL; Figure  1A ; Pϭ0.025). Based on previous reports that MPO levels in the placenta increase slowly with gestation, we limited our normal pregnancy group to match for gestational age of the sample (nϭ16; gestational age 37.5Ϯ0.3 weeks) and again found MPO concentrations in placental extracts from normal pregnancy to be much lower (286.5Ϯ66 ng/mL; Pϭ0.009).
Placental Immunolocalization of MPO
The localization of MPO within the placentas from normal and preeclamptic pregnancies was determined by immunohistochemical analysis. High levels of MPO were found in basal plates from 4 of 5 preeclampsia placentas compared with normal pregnancy placentas, where high levels were found 1 in 7 of placentas (representative slides are shown in Figure 1B, panel D versus B) . In the basal plate of women, degenerated cytotrophoblasts were MPO positive; however, in the preeclampsia basal plate, there was also strong staining of cytotrophoblasts and some as-yet-unidentified maternal cells. In the floating villi, MPO levels increased through gestation in normal pregnancies, and this increase was then compared with the MPO in placentas from patients with preeclampsia. Two third-trimester preeclampsia placentas had MPO staining greater than normal third-trimester placentas, and the remaining 3 preeclampsia placentas had MPO staining greater than normal term ( Figure 1C, panel D versus  B) . In the floating villi, MPO staining increased through gestation in the placentas from normal pregnancies, consistent with previous work. 27 This is shown in a representative placental sample at 7.5 weeks gestation ( Figure 1C , panel B) in comparison with 37.0 weeks ( Figure 1C, panel D) . Figure  1C 
MPO in Pregnancy Plasma
EDTA plasma samples from gestationally age-matched at delivery preeclamptic (nϭ11; 35.5 weeks gestation) and control normal pregnancies (nϭ13; 36.1 weeks gestation) were obtained for the determination of plasma MPO. Clinical data are provided in Table 2 . Plasma MPO levels were 3-fold higher in patients with preeclampsia compared with gestationally age-at delivery-matched normal control subjects (36.6Ϯ7.6 versus 11.0Ϯ3.1 ng/mL; Pϭ0.003; Figure 2A ) by ELISA (Calibiochem). Controlling for gestational age or protein levels did not influence these results. A second set of control patients with 2 samples collected during gestation (20 to 36 weeks) and at term were identified and used to determine whether MPO levels in plasma changed with normal gestation ( Figure 2B ). These samples were again compared with samples from patients with preeclampsia using a second ELISA assay system (Assay Designs). Plasma MPO levels were not significantly different earlier in gesta- tion compared with term in normal pregnancies (2.0Ϯ0.8 versus 5.0Ϯ1.4 ng/mL), whereas MPO in preeclampsia plasma was significantly elevated (32.5Ϯ11 ng/mL; Figure 2B ). We did not find any trend of increasing plasma MPO levels during gestation to term in the normal pregnancies. In normal pregnancy samples, 36% of patients had no change in MPO with resampling, 27% of patients had increased MPO levels, and 37% had decreased MPO levels with the second measurement. MPO concentrations measured by ELISA for preeclampsia patients were not significantly different between assays.
MPO in Postpartum Plasma
To determine the potential of MPO to bind to the vasculature of healthy reproductive-age women and whether preeclampsia-associated elevations in circulating MPO could be detected postpartum, we examined MPO levels in plasma from women postpregnancy before and after a heparin infusion (clinical data provided in Table 4 ), which would release heparin sulfate-bound MPO into the circulation. Heparin infusion resulted in a Ͼ5-fold increase in plasma MPO levels in the circulation 18.5Ϯ4 to 103.7Ϯ8 (nϭ16; PϽ0.001; Figure 3A ) in women with normal pregnancies and 20.1Ϯ5 to 114Ϯ10.3 in women with previous preeclampsia (nϭ15; PϽ0.001; Figure 3B ). There was no significant difference in plasma MPO levels or in the heparin-releasable levels in women with previous preeclamptic pregnancies compared with women with previous normal pregnancies at Ϸ1 year postpartum. Figure 1 . A, MPO levels in placental extracts. MPO levels were determined in placental extracts from patients with preeclampsia (nϭ27) and normal pregnancies (nϭ43). MPO levels were significantly greater in placental extracts from preeclampsia (546Ϯ62 ng/mL) vs normal control subjects with (287Ϯ66 ng/mL) or without (347Ϯ32 ng/mL) controlling for gestational age. Expressing MPO levels as nanograms per milliliter of extract or nanograms per milligram of protein did not change these results. MPO was examined immunohistochemically in basal plate (B) and floating villi (C) from placental samples. In B, the basal plates from normal pregnancy placenta at 37 weeks and from preeclampsia placenta (26 weeks) are shown with cytokeratin staining in A and C. MPO immunolocalization in normal pregnancy is shown in B and in preeclampsia (D). There was much greater MPO staining in the basal plate of preeclampsia vs normal pregnancy placenta. In the floating villi (C), A, C, and E are cytokeratin staining of samples from a 7.5-week normal pregnancy (A), 37.0-week normal pregnancy (C), and preeclampsia placentas (E). In floating villi from normal pregnancies, MPO staining increased with gestation from 7.5 weeks (B) to 37.0 weeks (D), whereas the preeclampsia placental sample had the highest levels of staining (F). MPO-positive cells were identified as primarily infiltrating white blood cells (cytokeratin-negative cells, shown in the inset of D) in normal pregnancy and white blood cells and syncytiotrophoblast (cytokeratin and MPO positive cells) in preeclampsia. Magnification is ϫ100 with a scale of size as indicated on the figures.
Discussion
MPO levels were significantly increased in placental extracts from women with preeclampsia. Placental MPO levels have been shown to increase with gestational age in the placenta for normal pregnancies. 27 MPO levels were significantly elevated when compared with gestationally age-matched placental samples without preeclampsia or normal term placental samples. The normal pregnancy data were limited to a sample set with matching gestational age to the preeclampsia group, resulting in a group of patients with early deliveries but without any evidence of pregnancy complications related to infection. This is consistent with the low concentrations of MPO measured in these patients. The high levels of MPO in the placental extracts were confirmed immunohistochemically; however, the samples used for the extract preparation did not include the basal plate, which was shown to have the most dramatic difference in MPO localization in the placental sections analyzed. The previous data on circulating MPO levels in patients with preeclampsia were conflicting 28 ; our data agree with studies reporting increased MPO in the circulation of women with preeclampsia. 1, 29 Unlike the placenta, circulating MPO levels did not significantly increase with gestation. The most plausible source of MPO in the circulation is activated inflammatory cells in either the circulation or tissue. We speculate that MPO may contribute to the oxidative damage reported in the endothelium of women with preeclampsia.
Once in the circulation, MPO can become sequestered in the subendothelial space through a process of heparin glycosaminoglycan-dependent binding and endothelial transcytosis, resulting in the accumulation of MPO in the endothelial cell matrix. 12 There it can be a potent source of reactive oxygen and nitrogen species. Functional significance of the vascular-associated MPO has been shown in patients undergoing coronary angiography for treatment of coronary artery disease. Baldus et al 30 found no significant difference in baseline plasma MPO levels, but on heparin infusion to release MPO from heparin glycosaminoglycan binding sites, circulating MPO levels were significantly higher in patients with coronary artery disease. Heparin infusion was also associated with improved NO-mediated endothelial function using flow-mediated dilation and responsiveness to acetylcholine. The heparin infusion was associated with a decrease in MPO burden in the vasculature of these patients. 30 We sought to determine the levels of heparin released in young women to assess the potential relevance of this mechanism in healthy patients and also to validate the determination of MPO in EDTA plasma samples from healthy patients. Our data also showed that, by 1 year postpartum, there was no significant difference in initial or heparin-releasable MPO in the circulation of previously preeclamptic women compared with women who had a normal pregnancy. These postpartum data indicate that there is no long-term mechanism of inflammation present in patients with preeclampsia that causes higher MPO levels compared with women with previous normal pregnancies, which remains in the postpartum period.
Perspectives
Elevations in MPO have not only been associated with cardiovascular events but have also been shown to have predictive power in high-risk patients. 9 Women with preeclampsia have numerous symptoms (hypertension, inflammation, and endothelial dysfunction) during pregnancy that can be associated with cardiovascular risk factors, and elevations in MPO in these patients may not only index the cardiovascular involvement of this disorder but may also play Figure 2 . MPO levels in plasma. A, MPO levels were significantly elevated in plasma of patients with preeclampsia (36.4Ϯ8 ng/mL; nϭ11) vs gestationally age-matched at delivery normal pregnant control subjects (11Ϯ3 ng/mL; nϭ13; Pϭ0.003) using an ELISA (Calbiochem). B, A second ELISA (Assay Designs) was used to confirm these results in the preeclampsia samples and a second group of normal pregnant control subjects with longitudinal samples at term (nϭ17), and samples not near delivery (nϭ17) during gestation matched for gestational age with preeclampsia samples. Again, preeclampsia plasma samples had significantly more MPO than control subjects when matched for gestational age (32.5Ϯ11 vs 2.0Ϯ0.8 ng/mL), and term samples were also lower than preeclampsia (5.0Ϯ1.4 ng/mL). Statistical analysis by Dunn's method.
a causative role. Further evaluation of the time course for elevations in MPO relative to hypertension in these patients should provide insight into the predictive power of MPO in pregnant women, as well as whether MPO may contribute mechanistically to the vascular dysfunction and hypertension in preeclampsia. Releasable MPO in healthy women with previous normal pregnancies or preeclampsia. A, Heparin infusion of postpartum women with previous normal pregnancies demonstrated a significant increase in plasma MPO levels after heparin treatment. B, MPO release also resulted in a significant increase in MPO in the circulation of postpartum women with previous preeclampsia. There was no significant difference in plasma MPO levels initially or after heparin treatment between women with previous normal pregnancies or preeclampsia at Ͼ1 year postpartum.
